These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 28422274)

  • 1. Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic graft-versus-host disease.
    Hurabielle C; Sicre de Fontbrune F; Moins-Teisserenc H; Robin M; Jachiet M; Coman T; Dhedin N; Cassius C; Chasset F; de Masson A; Michonneau D; Bagot M; Bergeron A; Socié G; Peffault de Latour R; Bouaziz JD
    Br J Dermatol; 2017 Nov; 177(5):e206-e208. PubMed ID: 28422274
    [No Abstract]   [Full Text] [Related]  

  • 2. Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective.
    Molés-Poveda P; Montesinos P; Sanz-Caballer J; de Unamuno B; Piñana JL; Sahuquillo A; Botella-Estrada R
    Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):241-247. PubMed ID: 29254596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of refractory sclerodermatous chronic graft-versus-host disease with intravenous lidocaine infusions.
    Phipps C; Lupo-Stanghellini MT; Flowers ME
    Bone Marrow Transplant; 2014 Feb; 49(2):315-6. PubMed ID: 24076547
    [No Abstract]   [Full Text] [Related]  

  • 4. Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD.
    de Masson A; Bouaziz JD; Peffault de Latour R; Wittnebel S; Ribaud P; Rubio MT; Micol JB; Suarez F; Nguyen S; Dalle JH; Yakouben K; Robin M; Xhaard A; Adès L; Bourhis JH; Rybojad M; Bagot M; Socié G
    Blood; 2012 Dec; 120(25):5089-90. PubMed ID: 23243159
    [No Abstract]   [Full Text] [Related]  

  • 5. Lack of efficacy of rituximab in refractory sclerodermatous chronic GVHD.
    George L; George B; Gottlieb DJ; Hertzberg M; Fernandez-Peñas P
    Bone Marrow Transplant; 2012 May; 47(5):737-8. PubMed ID: 21785472
    [No Abstract]   [Full Text] [Related]  

  • 6. Imatinib: A New Tool for the Management of Chronic Sclerodermatous Graft-Vs-Host Disease.
    Ferrándiz-Pulido C
    Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):200-201. PubMed ID: 29429550
    [No Abstract]   [Full Text] [Related]  

  • 7. Ruxolitinib in steroid-refractory chronic graft-versus-host disease: experience of a single center.
    Ferreira AM; Pontes da Silva CA; Pereira AD; Szor RS; Medeiros da Fonseca ARB; Serpa MG; Xavier EM; Sampaio de Melo MK; Novis Y; Tucunduva L; Rocha V; Arrais-Rodrigues C
    Bone Marrow Transplant; 2018 Apr; 53(4):503-506. PubMed ID: 29330403
    [No Abstract]   [Full Text] [Related]  

  • 8. [Sclerodermatous cutaneous reaction of graft vs host disease treated with thalidomide].
    Pédailles S; Troussard X; Launay V; Bazin A; Sentias C; Surbled M
    Presse Med; 1993 Jan 2-16; 22(1):37. PubMed ID: 8469665
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.
    Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
    Front Immunol; 2021; 12():673636. PubMed ID: 34276662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sclerodermatous chronic graft-versus-host disease--a report of four pediatric cases.
    Tolland JP; Devereux C; Jones FC; Bingham EA
    Pediatr Dermatol; 2008; 25(2):240-4. PubMed ID: 18429789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease.
    Moreno-Romero JA; Fernández-Avilés F; Carreras E; Rovira M; Martínez C; Mascaró JM
    Arch Dermatol; 2008 Sep; 144(9):1106-9. PubMed ID: 18794453
    [No Abstract]   [Full Text] [Related]  

  • 12. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
    Zeiser R; Polverelli N; Ram R; Hashmi SK; Chakraverty R; Middeke JM; Musso M; Giebel S; Uzay A; Langmuir P; Hollaender N; Gowda M; Stefanelli T; Lee SJ; Teshima T; Locatelli F;
    N Engl J Med; 2021 Jul; 385(3):228-238. PubMed ID: 34260836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete remission of sclerodermatous cutaneous graft-versus-host disease after low-dose interleukine-2 treatment.
    Weiss M; de Masson A; Robin M; Peffault de Latour R; Bagot M; Socié G; Bouaziz JD
    J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):e791-e793. PubMed ID: 32329912
    [No Abstract]   [Full Text] [Related]  

  • 14. Localized edema with sclerodermatous evolution: a possible form of skin chronic graft-versus-host disease associated with endothelial activation.
    Tardieu M; Rybojad M; Peffault de Latour R; Robin M; de Masson A; Xhaard A; Le Buanec H; Parquet N; Sicre de Fontbrune F; Bergeron A; Scieux C; Dessirier V; Bensussan A; Bagot M; Socié G; Bouaziz JD
    Blood; 2013 Jul; 122(3):463-5. PubMed ID: 23869081
    [No Abstract]   [Full Text] [Related]  

  • 15. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
    von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
    BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ruxolitinib in children with steroid-refractory acute graft-versus-host disease: A retrospective multicenter study of the pediatric group of SFGM-TC.
    Laisne L; Neven B; Dalle JH; Galambrun C; Esvan M; Renard C; Rialland F; Sirvent A; Gandemer V;
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28233. PubMed ID: 32614145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.
    Mozo Y; Bueno D; Sisinni L; Fernández-Arroyo A; Rosich B; Martínez AP; Benítez-Carabante MI; Alonso L; Uría ML; Heredia CD; Mestre-Duran C; Pascual CFB; Torres J; Losantos I; Escudero A; Ruz-Caracuel B
    Pediatr Hematol Oncol; 2021 May; 38(4):331-345. PubMed ID: 33661711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of Sclerodermatous Graft-Versus-Host Disease in Mice by Niclosamide.
    Morin F; Kavian N; Nicco C; Cerles O; Chéreau C; Batteux F
    J Invest Dermatol; 2016 Nov; 136(11):2158-2167. PubMed ID: 27424318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sclerodermatous changes of chronic graft-versus-host-disease treated with puva.
    Woscoff A; Ruíz Lascano A; De Pablo AB; Robinson A
    Int J Dermatol; 1996 Sep; 35(9):656-8. PubMed ID: 8876297
    [No Abstract]   [Full Text] [Related]  

  • 20. Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study.
    Escamilla Gómez V; García-Gutiérrez V; López Corral L; García Cadenas I; Pérez Martínez A; Márquez Malaver FJ; Caballero-Velázquez T; González Sierra PA; Viguria Alegría MC; Parra Salinas IM; Calderón Cabrera C; González Vicent M; Rodríguez Torres N; Parody Porras R; Ferra Coll C; Orti G; Valcárcel Ferreiras D; De la Cámara LLanzá R; Molés P; Velázquez-Kennedy K; João Mende M; Caballero Barrigón D; Pérez E; Martino Bofarull R; Saavedra Gerosa S; Sierra J; Poch M; Zudaire Ripa MT; Díaz Pérez MA; Molina Angulo B; Sánchez Ortega I; Sanz Caballer J; Montoro Gómez J; Espigado Tocino I; Pérez-Simón JA;
    Bone Marrow Transplant; 2020 Mar; 55(3):641-648. PubMed ID: 31700138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.